Literature DB >> 21466501

Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.

Michael A Yokell1, Nickolas D Zaller, Traci C Green, Josiah D Rich.   

Abstract

The diversion, misuse, and non-medically supervised use of buprenorphine and buprenorphine/naloxone by opioid users are reviewed. Buprenorphine and buprenorphine/naloxone are used globally as opioid analgesics and in the treatment of opioid dependency. Diversion of buprenorphine and buprenorphine/naloxone represents a complex medical and social issue, and has been widely documented in various geographical regions throughout the world. We first discuss the clinical properties of buprenorphine and its abuse potential. Second, we discuss its diversion and illicit use on an international level, as well as motivations for those activities. Third, we examine the medical risks and benefits of buprenorphine's non-medically supervised use and misuse. These risks and benefits include the effect of buprenorphine's use on HIV risk and the risk of its concomitant use with other medications and drugs of abuse. Finally, we discuss the implications of diversion, misuse, and non-medically supervised use (including potential measures to address issues of diversion); and potential areas for further research.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21466501      PMCID: PMC3154701          DOI: 10.2174/1874473711104010028

Source DB:  PubMed          Journal:  Curr Drug Abuse Rev        ISSN: 1874-4737


  119 in total

Review 1.  Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?

Authors:  John Mendelson; Reese T Jones
Journal:  Drug Alcohol Depend       Date:  2003-05-21       Impact factor: 4.492

2.  Abuse of buprenorphine (Temgesic) by snorting.

Authors:  J Strang
Journal:  BMJ       Date:  1991-04-20

3.  Earlier warning: a multi-indicator approach to monitoring trends in the illicit use of medicines.

Authors:  Jane Mounteney; Siren Haugland
Journal:  Int J Drug Policy       Date:  2007-11-26

4.  A controlled trial of buprenorphine treatment for opioid dependence.

Authors:  R E Johnson; J H Jaffe; P J Fudala
Journal:  JAMA       Date:  1992-05-27       Impact factor: 56.272

Review 5.  Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection.

Authors:  Linda R Gowing; Michael Farrell; Reinhard Bornemann; Lynn E Sullivan; Robert L Ali
Journal:  J Gen Intern Med       Date:  2005-12-07       Impact factor: 5.128

6.  Prescription opioid abuse among enrollees into methadone maintenance treatment.

Authors:  Andrew Rosenblum; Mark Parrino; Sidney H Schnoll; Chunki Fong; Carleen Maxwell; Charles M Cleland; Stephen Magura; J David Haddox
Journal:  Drug Alcohol Depend       Date:  2007-03-26       Impact factor: 4.492

7.  Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence.

Authors:  Jason White; James Bell; John B Saunders; Paul Williamson; Maria Makowska; Aaron Farquharson; Katherine L Beebe
Journal:  Drug Alcohol Depend       Date:  2009-04-28       Impact factor: 4.492

8.  Cutaneous complications among i.v. buprenorphine users.

Authors:  Roger C M Ho; Emily C L Ho; Anselm Mak
Journal:  J Dermatol       Date:  2009-01       Impact factor: 4.005

9.  Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.

Authors:  W K Bickel; M L Stitzer; G E Bigelow; I A Liebson; D R Jasinski; R E Johnson
Journal:  J Pharmacol Exp Ther       Date:  1988-10       Impact factor: 4.030

10.  Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: an open-label evaluation.

Authors:  Ryan K Lanier; Annie Umbricht; Joseph A Harrison; Elie S Nuwayser; George E Bigelow
Journal:  Psychopharmacology (Berl)       Date:  2008-03-09       Impact factor: 4.530

View more
  66 in total

1.  Validity of Self-Reported Drug Use Information Among Pregnant Women.

Authors:  Mahek Garg; Laura Garrison; Lawrence Leeman; Ajna Hamidovic; Matthew Borrego; William F Rayburn; Ludmila Bakhireva
Journal:  Matern Child Health J       Date:  2016-01

2.  "Sub is a weird drug:" A web-based study of lay attitudes about use of buprenorphine to self-treat opioid withdrawal symptoms.

Authors:  Raminta Daniulaityte; Robert Carlson; Gregory Brigham; Delroy Cameron; Amit Sheth
Journal:  Am J Addict       Date:  2015-05-25

3.  Opiate withdrawal syndrome in buprenorphine abusers admitted to a rehabilitation center in Tunisia.

Authors:  Ines Derbel; Asma Ghorbel; Férièle Messadi Akrout; Abdelmajid Zahaf
Journal:  Afr Health Sci       Date:  2016-12       Impact factor: 0.927

4.  Practice Guidance for Buprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process.

Authors:  Carrie M Farmer; Dawn Lindsay; Jessica Williams; Amanda Ayers; James Schuster; Alyssa Cilia; Michael T Flaherty; Todd Mandell; Adam J Gordon; Bradley D Stein
Journal:  Subst Abus       Date:  2015-04-06       Impact factor: 3.716

5.  Assessment of Racial/Ethnic and Income Disparities in the Prescription of Opioids and Other Controlled Medications in California.

Authors:  Joseph Friedman; David Kim; Todd Schneberk; Philippe Bourgois; Michael Shin; Aaron Celious; David L Schriger
Journal:  JAMA Intern Med       Date:  2019-04-01       Impact factor: 21.873

6.  Buprenorphine treatment for narcotic addiction: not without risks.

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Innov Clin Neurosci       Date:  2015 Mar-Apr

7.  A urinalysis-based comparative study of treatment adherence on buprenorphine and buprenorphine/naloxone combination used as opioid substitution therapy.

Authors:  Yatan Pal Singh Balhara; Raka Jain
Journal:  Innov Clin Neurosci       Date:  2012-07

Review 8.  Buprenorphine-naloxone therapy in pain management.

Authors:  Kelly Yan Chen; Lucy Chen; Jianren Mao
Journal:  Anesthesiology       Date:  2014-05       Impact factor: 7.892

9.  Patterns of non-prescribed buprenorphine and other opioid use among individuals with opioid use disorder: A latent class analysis.

Authors:  Raminta Daniulaityte; Ramzi W Nahhas; Sydney Silverstein; Silvia Martins; Angela Zaragoza; Avery Moeller; Robert G Carlson
Journal:  Drug Alcohol Depend       Date:  2019-09-22       Impact factor: 4.492

10.  Consumer attitudes about opioid addiction treatment: a focus group study in New York City.

Authors:  Nancy L Sohler; Linda Weiss; James E Egan; Carolina M López; Jamie Favaro; Robert Cordero; Chinazo O Cunningham
Journal:  J Opioid Manag       Date:  2013 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.